** Shares of Artrya fall as much 9% to A$0.455, their lowest level since Oct 23
** The medical technology co receives firm commitments to raise A$5 mln ($3.29 mln) via placement
** Issue price of A$0.42 represents 16% discount to co's last close on Thursday, Nov. 7
** Adds, fund raised to be allocated to product development, others, as co awaits FDA clearance on its patented Salix Coronary Anatomy product
** Stock up 95.8% this year, including session's moves
($1 = 1.5221 Australian dollars)
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.